PortalPublikationenPlasma miR-122 and miR-200 family are prognostic markers in ...

Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer

Standard

Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. / Maierthaler, Melanie; Benner, Axel; Hoffmeister, Michael; Surowy, Harald; Jansen, Lina; Knebel, Phillip; Chang-Claude, Jenny; Brenner, Hermann; Burwinkel, Barbara.

in: INT J CANCER, Jahrgang 140, Nr. 1, 01.01.2017, S. 176-187.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Maierthaler, M, Benner, A, Hoffmeister, M, Surowy, H, Jansen, L, Knebel, P, Chang-Claude, J, Brenner, H & Burwinkel, B 2017, 'Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer', INT J CANCER, Jg. 140, Nr. 1, S. 176-187. https://doi.org/10.1002/ijc.30433

APA

Maierthaler, M., Benner, A., Hoffmeister, M., Surowy, H., Jansen, L., Knebel, P., Chang-Claude, J., Brenner, H., & Burwinkel, B. (2017). Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. INT J CANCER, 140(1), 176-187. https://doi.org/10.1002/ijc.30433

Vancouver

Maierthaler M, Benner A, Hoffmeister M, Surowy H, Jansen L, Knebel P et al. Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. INT J CANCER. 2017 Jan 1;140(1):176-187. https://doi.org/10.1002/ijc.30433

Bibtex

@article{dc79177084104147b78c864520e7ecf9,
title = "Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer",
abstract = "Circulating microRNAs (miRNAs) have been proposed as minimally invasive prognostic markers for various types of cancers, including colorectal cancer (CRC), the third most diagnosed cancer worldwide. We aimed to evaluate the levels of circulating miRNAs that might serve as markers for CRC prognosis and survival. We included plasma samples of 543 CRC patients with stage I-IV disease from a population-based study carried out in Germany. After comprehensive evaluation of current literature, 95 miRNAs were selected and measured with Custom TaqMan{\textregistered} Array MicroRNA Cards. Plasma samples of non-metastatic and metastatic colon cancer patients, each group consisting of ten patients with 'good' and ten patients with 'bad' prognosis were screened. Identified candidate miRNAs were further validated by RT-qPCR in the whole study cohort. The association of the miRNA levels with patients' survival and the prognostic subtypes was analyzed with uni- and multivariate logistic regression and Cox proportional hazards regression models. Increased miR-122 levels were associated with a 'bad' prognostic subtype in metastatic CRC (Odds ratio: 1.563, 95% confidence interval (CI): 1.038-2.347) and a shorter relapse-free survival and overall survival for non-metastatic (Hazard ratio (HR): 1.370, 95% CI: 1.028-1.825; HR: 1.353, 95% CI: 1.002-1.828) and metastatic (HR: 1.264, 95% CI: 1.050-1.520; HR: 1.292, 95% CI: 1.078-1.548) CRC patients. Additionally, several members of the miR-200 family showed associations with patients' prognosis and correlations to clinicopathological characteristics. The here identified miRNA markers, miR-122 and the miR-200 family members, could be of use in the development of a multi-marker blood test for CRC prognosis.",
keywords = "Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Case-Control Studies, Colorectal Neoplasms, Female, Germany, Humans, Male, MicroRNAs, Middle Aged, Multigene Family, Neoplasm Metastasis, Prognosis, Survival Analysis, Journal Article",
author = "Melanie Maierthaler and Axel Benner and Michael Hoffmeister and Harald Surowy and Lina Jansen and Phillip Knebel and Jenny Chang-Claude and Hermann Brenner and Barbara Burwinkel",
note = "{\textcopyright} 2016 UICC.",
year = "2017",
month = jan,
day = "1",
doi = "10.1002/ijc.30433",
language = "English",
volume = "140",
pages = "176--187",
journal = "INT J CANCER",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer

AU - Maierthaler, Melanie

AU - Benner, Axel

AU - Hoffmeister, Michael

AU - Surowy, Harald

AU - Jansen, Lina

AU - Knebel, Phillip

AU - Chang-Claude, Jenny

AU - Brenner, Hermann

AU - Burwinkel, Barbara

N1 - © 2016 UICC.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Circulating microRNAs (miRNAs) have been proposed as minimally invasive prognostic markers for various types of cancers, including colorectal cancer (CRC), the third most diagnosed cancer worldwide. We aimed to evaluate the levels of circulating miRNAs that might serve as markers for CRC prognosis and survival. We included plasma samples of 543 CRC patients with stage I-IV disease from a population-based study carried out in Germany. After comprehensive evaluation of current literature, 95 miRNAs were selected and measured with Custom TaqMan® Array MicroRNA Cards. Plasma samples of non-metastatic and metastatic colon cancer patients, each group consisting of ten patients with 'good' and ten patients with 'bad' prognosis were screened. Identified candidate miRNAs were further validated by RT-qPCR in the whole study cohort. The association of the miRNA levels with patients' survival and the prognostic subtypes was analyzed with uni- and multivariate logistic regression and Cox proportional hazards regression models. Increased miR-122 levels were associated with a 'bad' prognostic subtype in metastatic CRC (Odds ratio: 1.563, 95% confidence interval (CI): 1.038-2.347) and a shorter relapse-free survival and overall survival for non-metastatic (Hazard ratio (HR): 1.370, 95% CI: 1.028-1.825; HR: 1.353, 95% CI: 1.002-1.828) and metastatic (HR: 1.264, 95% CI: 1.050-1.520; HR: 1.292, 95% CI: 1.078-1.548) CRC patients. Additionally, several members of the miR-200 family showed associations with patients' prognosis and correlations to clinicopathological characteristics. The here identified miRNA markers, miR-122 and the miR-200 family members, could be of use in the development of a multi-marker blood test for CRC prognosis.

AB - Circulating microRNAs (miRNAs) have been proposed as minimally invasive prognostic markers for various types of cancers, including colorectal cancer (CRC), the third most diagnosed cancer worldwide. We aimed to evaluate the levels of circulating miRNAs that might serve as markers for CRC prognosis and survival. We included plasma samples of 543 CRC patients with stage I-IV disease from a population-based study carried out in Germany. After comprehensive evaluation of current literature, 95 miRNAs were selected and measured with Custom TaqMan® Array MicroRNA Cards. Plasma samples of non-metastatic and metastatic colon cancer patients, each group consisting of ten patients with 'good' and ten patients with 'bad' prognosis were screened. Identified candidate miRNAs were further validated by RT-qPCR in the whole study cohort. The association of the miRNA levels with patients' survival and the prognostic subtypes was analyzed with uni- and multivariate logistic regression and Cox proportional hazards regression models. Increased miR-122 levels were associated with a 'bad' prognostic subtype in metastatic CRC (Odds ratio: 1.563, 95% confidence interval (CI): 1.038-2.347) and a shorter relapse-free survival and overall survival for non-metastatic (Hazard ratio (HR): 1.370, 95% CI: 1.028-1.825; HR: 1.353, 95% CI: 1.002-1.828) and metastatic (HR: 1.264, 95% CI: 1.050-1.520; HR: 1.292, 95% CI: 1.078-1.548) CRC patients. Additionally, several members of the miR-200 family showed associations with patients' prognosis and correlations to clinicopathological characteristics. The here identified miRNA markers, miR-122 and the miR-200 family members, could be of use in the development of a multi-marker blood test for CRC prognosis.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Biomarkers, Tumor

KW - Case-Control Studies

KW - Colorectal Neoplasms

KW - Female

KW - Germany

KW - Humans

KW - Male

KW - MicroRNAs

KW - Middle Aged

KW - Multigene Family

KW - Neoplasm Metastasis

KW - Prognosis

KW - Survival Analysis

KW - Journal Article

U2 - 10.1002/ijc.30433

DO - 10.1002/ijc.30433

M3 - SCORING: Journal article

C2 - 27632639

VL - 140

SP - 176

EP - 187

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 1

ER -